Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.

person Matthew J. Monberg Merck & Co., Inc., Kenilworth, NJ info_outline Matthew J. Monberg, Jennifer P Hall, Rebecca Moon, Olivia Higson, Kimmie McLaurin, Tapashi Dalvi

Authors person Matthew J. Monberg Merck & Co., Inc., Kenilworth, NJ info_outline Matthew J. Monberg, Jennifer P Hall, Rebecca Moon, Olivia Higson, Kimmie McLaurin, Tapashi Dalvi Organizations Merck & Co., Inc., Kenilworth, NJ, Adelphi Real World, Manchester, United Kingdom, AstraZeneca Pharmaceuticals, LP, Gaithersburg, MD Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Background: Bevacizumab (B) is approved in combination with carboplatin and paclitaxel, followed by B monotherapy, for the treatment of advanced ovarian cancer (OC) following surgery. We sought to describe B utilization and outcomes of B in first-line (1L) OC within the US and EU. Methods: This cross-sectional study included patients who were actively receiving treatment for OC. Data were collected at a single time point from 2496 patient forms between December 2017 and March 2018 from 340 oncologists/ gynecologists across the US, France, Germany, Italy, Spain, and the UK. Patients were platinum sensitive if progression was noted > 6 months after frontline platinum therapy and resistant if the interval was 0-6 months. This analysis included patients who received 1L chemotherapy (chemo) with no maintenance or 1L chemo with bevacizumab maintenance. Results: B was used in combination with chemo at 1L and as 1L maintenance monotherapy in 11% total study patients. Those receiving 1L + B were more likely to have Stage IV disease, have good performance status (PS) at diagnosis, and receive BRCA testing than patients receiving chemo only. Treatment response, platinum sensitivity, and activities of daily living are shown in the Table. Results did not vary by BRCA status. Conclusions: This study highlights differences in patient characteristics and outcomes between patients receiving/ who received 1L chemo only and those receiving/ who received B, however, this study was not designed to formally compare 1L treatment options. Total 1L Chemo Only Treatment + No 1L maintenance 1L Chemo + B + B Maintenance N who initiated 1L 1498 1232 266 Mean age, yrs 64 64 61 Stage IV, % 65 63 76 ECOG PS 0-1 at diagnosis, % 81 78 92 BRCA tested, % 52 47 71 BRCA positive of those screened, % 24 25 22 Some decrease in activities of daily living, % 73 73 71 N who completed 1L 945 742 203 Complete response, partial response or stable disease at completion of 1L, % 83 79 96 Platinum sensitive, % 40 35 58 Platinum resistant, % 14 13 15 Platinum refractory, % 14 17 4 Received 2L platinum, % 61 58 72 Received 2L nonplatinum, % 39 42 28 Mean 1L completed treatment duration, months (N) 4.9 (634) 5.1 (434) 4.4 (200) Mean 1L completed maintenance duration, months (N) 8.3 (149) NA (NA) 8.3 (149) Mean time off treatment between 1-2 years of diagnosis, months (N) 6.3 (221) 8.4 (142) 2.7 (79)